Reports Q1: OD-001 Phase IIb And Phase IIa Vedo Combo On Track To Start In H2

Research evidence excerpt

Reports Q1: OD-001 Phase IIb And Phase IIa Vedo Combo On Track To Start In H2

Biotechnology

Odyssey Therapeutics

TD SECURITIES (USA) LLC EARNINGS UPDATE

June 18, 2026

Price: $18.48 (06/17/2026) Reports Q1: OD-001 Phase IIb And Phase IIa

Price Target: NA Vedo Combo On Track To Start In H2

BUY (1)

ESG SCORE: 63/100

Tyler Van Buren THE TD COWEN INSIGHT

646 562 1343

Odyssey reported compelling OD-001 data in UC, with a 27% remission rate and strong

tyler.vanburen@tdsecurities.com

efficacy in AT-exp patients, underscoring the potential of its novel MoA (RIPK2 scaffolding

Sam Rollenhagen inhibitor). These data will be presented at a meeting in H2, and a Phase IIb mono and a Phase

212 468 7785 IIa vedo combo study are on track to start in H2 (data in '27). The SLC15A4 inhibitor is exciting

samuel.rollenhagen@tdsecurities.com

& should enter Phase I in 2027.

Nicholas Lorusso

646 562 1390 Read our initiation report on Odyssey from early June here.

nick.lorusso@tdsecurities.com

OD-001's Phase IIa Data Demonstrated Compelling Clinical Profile Of A Safe, Effective Oral

Greg W. Torres, Ph.D. With A Novel RIPK2 MoA In IBD

646 562 1351

gregory.wiessner@tdsecurities.com Odyssey is led by a group of elite drug hunters, biologists, and chemists, many of whom

previously worked together in successful multi-$B exits. The lead asset, OD-001, is an oral

Ikenna Okafor, Ph.D.

RIPK2 scaffolding inhibitor for the treatment of IBD. RIPK2 is a key signaling node in IBD646 562 1395

ikenna.okafor@tdsecurities.com that links innate immune system activation to downstream adaptive signaling, where SoC

agents (TNF, IL23, TL1A) act today. Others have failed to drug it previously, but Odyssey knew

Key Data

activation was caused by XIAP scaffolding (not kinase function) and is now the only known